A Conshohocken-based pharmaceutical company’s treatment for nonalcoholic steatoheptatitis (NASH) a severe form of liver disease, is getting priority review by the Food & Drug Administration according to a press release.
Madrigal Pharmaceutical’s Resmeitrom is an oral thyroid hormone receptor that targets underlying causes of the disease in adults who have NASH with liver fibrosis. It has been assigned a Prescription Drug User Fee Act for March of 2024, when the FDA plans to complete the review.
CEO Bill Sibold says that this condition is an unmet need, and without treatment can lead to liver failure, liver failure, or premature mortality.
“The FDA’s acceptance of our NDA with priority review is an important step forward as we pursue our goal of delivering the first approved treatment to patients with NASH with liver fibrosis,” he said.
Read more about this groundbreaking treatment on Yahoo! Finance.
Understanding NASH by Madrigal Pharmaceuticals.
